Martina Sassone-Corsi

Martina Sassone-Corsi

Auto-generated profile, based on publicly available information

Martina Sassone-Corsi

Department of Microbiology & Molecular Genetics, University of California Irvine, Irvine, California 92697, United States

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2016 in Nature
Verified
Journal Article
Open access
PDF file
MSMartina Sassone-Corsi
Martina Sassone-Corsi
SNSean-Paul Nuccio
Sean-Paul Nuccio
HLHenry Liu
Henry Liu
DHDulcemaria Hernandez
Dulcemaria Hernandez
CVChristine T. Vu
Christine T. Vu
MRManuela Raffatellu
Manuela Raffatellu
Certain commensal enterobacteria secrete small proteins called microcins that suppress the growth of other bacteria in the inflamed gut, conferring an intra- and interspecies competitive advantage. Microcins are small secreted proteins composed of relatively few peptides, secreted by certain commensal enterobacteria . They are known to be antimicrobial in vitro, but their role in vivo is unclear. This study shows that microcin expression enables the probiotic bacteria, Escherichia coli, to limit expansion of competing Enterobacteriaceae during intestinal inflammation. Therapeutic administration of microcin-producing bacteria substantially reduced intestinal colonization of pathogenic bacteria in mice. This is the first evidence that microcins mediate inter- and intra-species competition and may be useful as narrow-spectrum therapeutics to inhibit enteric pathogens and reduce enterobacterial blooms. The Enterobacteriaceae are a family of Gram-negative bacteria that include commensal organisms as well as primary and opportunistic pathogens that are among the leading causes of morbidity and mortality worldwide. Although Enterobacteriaceae often comprise less than 1% of a healthy intestine’s microbiota1, some of these organisms can bloom in the inflamed gut2,3,4,5; expansion of enterobacteria is a hallmark of microbial imbalance known as dysbiosis6. Microcins are small secreted proteins that possess antimicrobial activity in vitro7,8, but whose role in vivo has been unclear. Here we demonstrate that microcins enable the probiotic bacterium Escherichia coli Nissle 1917 (EcN) to limit the expansion of competing Enterobacteriaceae (including pathogens and pathobionts) during intestinal inflammation. Microcin-producing EcN limits the growth of competitors in the inflamed intestine, including commensal E. coli, adherent–invasive E. coli and the related pathogen Salmonella enterica. Moreover, only therapeutic administration of the wild-type, microcin-producing EcN to mice previously infected with S. enterica substantially reduced intestinal colonization by the pathogen. Our work provides the first evidence that microcins mediate inter- and intraspecies competition among the Enterobacteriaceae in the inflamed gut. Moreover, we show that microcins can act as narrow-spectrum therapeutics to inhibit enteric pathogens and reduce enterobacterial blooms.

1 May 2015 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MSMartina Sassone-Corsi
Martina Sassone-Corsi
MRManuela Raffatellu
Manuela Raffatellu
The mammalian intestine harbors a community of trillions of microbes, collectively known as the gut microbiota, which coevolved with the host in a mutually beneficial relationship. Among the numerous gut microbial species, certain commensal bacteria are known to provide health benefits to the host when administered in adequate amounts and, as such, are labeled “probiotics.” We review some of the mechanisms by which probiotics and other beneficial commensals provide colonization resistance to pathogens. The battle for similar nutrients and the bacterial secretion of antimicrobials provide a direct means of competition between beneficial and harmful microbes. Beneficial microbes can also indirectly diminish pathogen colonization by stimulating the development of innate and adaptive immunity, as well as the function of the mucosal barrier. Altogether, we gather and present evidence that beneficial microbes cooperate with host immunity in an effort to shut out pathogens.

1 March 2013 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Closed access
PDF file
JBJudith Behnsen
Judith Behnsen
EDElisa Deriu
Elisa Deriu
MSMartina Sassone-Corsi
Martina Sassone-Corsi
MRManuela Raffatellu
Manuela Raffatellu
Probiotics are beneficial components of the microbiota that have been used for centuries because of the health benefits they confer to the host. Only recently, however, has the contribution of probiotics to modulation of immunological, respiratory, and gastrointestinal functions started to be fully appreciated and scientifically evaluated. Probiotics such as Escherichia coli Nissle 1917 and lactic acid bacteria are currently used to, or have been evaluated for use to, prevent or treat a range of intestinal maladies including inflammatory bowel disease, constipation, and colon cancer. Engineering these natural probiotics to produce immunomodulatory molecules may help to further increase the benefit to the host. In this article, we will discuss some of the mechanisms of action of probiotics as well as advances in the rational design of probiotics.

26 March 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
WNWilma Neumann
Wilma Neumann
MSMartina Sassone-Corsi
Martina Sassone-Corsi
MRManuela Raffatellu
Manuela Raffatellu
ENElizabeth M. Nolan
Elizabeth M. Nolan

7 November 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MSMartina Sassone-Corsi
Martina Sassone-Corsi
PCPhoom Chairatana
Phoom Chairatana
TZTengfei Zheng
Tengfei Zheng
APAraceli Perez-Lopez
Araceli Perez-Lopez
RERobert A. Edwards
Robert A. Edwards
MRManuela Raffatellu
Manuela Raffatellu
Significance: Gram-negative pathogens represent a major public health issue. With increases in antibiotic resistance and the limited availability of preventive strategies, new ways are needed to target these bacteria. Here, we propose a narrow-spectrum immunization strategy to block the ability of a gastrointestinal pathogen to acquire the essential metal nutrient iron. This approach involves the chemical synthesis of bacterial iron chelators, known as siderophores, and their conjugation to immunogenic carrier proteins. Mice immunized with these compounds developed antibodies against siderophores in the intestine, which hindered proliferation of the gut pathogen Salmonella . Because similar but distinct molecules are secreted by many bacterial and fungal pathogens, this synthesis and immunization strategy could be applied to a broad range of infectious agents.

10 March 2021 in ACS Infectious Diseases
Verified
Journal Article
Closed access
ASArtur Sargun
Artur Sargun
MSMartina Sassone-Corsi
Martina Sassone-Corsi
TZTengfei Zheng
Tengfei Zheng
MRManuela Raffatellu
Manuela Raffatellu
ENElizabeth M. Nolan
Elizabeth M. Nolan